In the TCGA AML cohort, AML patients with KIT mutations and RUNX1 mutations had a significantly higher expression levels of TRH compared with the wild-type groups (p = 0.0023 and p = 0.047, respectively) (Figure 3b and Figure S4). This evidence concerns the gene TRH and acute myeloid leukemia.